BRPI0818511A2 - Novos compostos de miméticos de giro reverso e uso dos mesmos (1) - Google Patents

Novos compostos de miméticos de giro reverso e uso dos mesmos (1)

Info

Publication number
BRPI0818511A2
BRPI0818511A2 BRPI0818511-5A BRPI0818511A BRPI0818511A2 BR PI0818511 A2 BRPI0818511 A2 BR PI0818511A2 BR PI0818511 A BRPI0818511 A BR PI0818511A BR PI0818511 A2 BRPI0818511 A2 BR PI0818511A2
Authority
BR
Brazil
Prior art keywords
gyretic
mimetics
reverse
new compounds
compounds
Prior art date
Application number
BRPI0818511-5A
Other languages
English (en)
Inventor
Jae Uk Chung
Hee-Kyung Jung
Kyung-Yun Jung
Min-Wook Jeong
Hyun-Ju La
Sang-Hak Lee
Hoe-Moon Kim
Original Assignee
Choongwae Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongwae Pharma Corp filed Critical Choongwae Pharma Corp
Publication of BRPI0818511A2 publication Critical patent/BRPI0818511A2/pt
Publication of BRPI0818511B1 publication Critical patent/BRPI0818511B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0818511-5A 2007-10-15 2008-10-15 Compostos de miméticos de giro reverso e uso dos mesmos para tratar ou prevenir leucemia mielóide aguda BRPI0818511B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/974,941 US7671054B1 (en) 2001-10-12 2007-10-15 Reverse-turn mimetics and method relating thereto
US11/974.941 2007-10-15
PCT/KR2008/006072 WO2009051399A2 (en) 2007-10-15 2008-10-15 Novel compounds of reverse turn mimetics and the use thereof (1)

Publications (2)

Publication Number Publication Date
BRPI0818511A2 true BRPI0818511A2 (pt) 2015-06-16
BRPI0818511B1 BRPI0818511B1 (pt) 2021-09-21

Family

ID=40567948

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0818647-2A BRPI0818647B1 (pt) 2007-10-15 2008-10-15 Compostos de miméticos de volta reversa e uso dos mesmos para tratar ou prevenir leucemia mielóide aguda
BRPI0818511-5A BRPI0818511B1 (pt) 2007-10-15 2008-10-15 Compostos de miméticos de giro reverso e uso dos mesmos para tratar ou prevenir leucemia mielóide aguda

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0818647-2A BRPI0818647B1 (pt) 2007-10-15 2008-10-15 Compostos de miméticos de volta reversa e uso dos mesmos para tratar ou prevenir leucemia mielóide aguda

Country Status (13)

Country Link
US (4) US7671054B1 (pt)
EP (3) EP2212328B1 (pt)
JP (3) JP5400785B2 (pt)
KR (3) KR101269420B1 (pt)
CN (4) CN101827850B (pt)
AU (2) AU2008312191B2 (pt)
BR (2) BRPI0818647B1 (pt)
CA (2) CA2701735C (pt)
ES (3) ES2622703T3 (pt)
MX (2) MX2010004045A (pt)
PL (1) PL2212330T3 (pt)
RU (2) RU2457210C2 (pt)
WO (3) WO2009051399A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3211496B2 (ja) 1993-07-30 2001-09-25 日産自動車株式会社 表面潤滑皮膜処理材およびその製造方法
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
WO2007056593A2 (en) * 2005-11-08 2007-05-18 Choongwae Pharma Corporation α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS
JP5530427B2 (ja) * 2008-06-06 2014-06-25 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ アルファへリックスミメティック及び関連の方法
US8691819B2 (en) 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
SG175045A1 (en) * 2009-04-15 2011-11-28 Jw Pharmaceutical Corp Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
WO2010128685A1 (en) 2009-05-07 2010-11-11 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
JPWO2011096440A1 (ja) 2010-02-03 2013-06-10 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 天然変性タンパク質に結合する化合物およびそのスクリーニング方法
KR102168006B1 (ko) 2010-10-07 2020-10-20 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
ES2552462T3 (es) * 2010-10-14 2015-11-30 Jw Pharmaceutical Corporation Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
AU2011329854B2 (en) 2010-11-16 2017-03-30 University Of Southern California CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
WO2012115286A1 (en) * 2011-02-25 2012-08-30 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
JP2014513071A (ja) * 2011-04-04 2014-05-29 シエナ ビオテク ソシエタ ペル アチオニ ウィント経路遮断薬
KR101441406B1 (ko) * 2011-05-25 2014-11-04 주식회사 바이오이미징코리아 디아릴이오도늄 염 전구체를 이용한 플로오린-18이 표지된 플루마제닐의 제조 방법
US9353119B2 (en) * 2011-08-09 2016-05-31 Jw Pharmaceutical Corporation Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
ES2577863T3 (es) 2011-08-09 2016-07-19 Jw Pharmaceutical Corporation Composición para la prevención y el tratamiento del cáncer de pulmón de células no pequeñas, que contiene derivados de pirazino-triazina
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
CA2851187A1 (en) 2011-10-07 2013-04-11 University Of Southern California Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
SG11201601767YA (en) * 2013-09-11 2016-04-28 Prism Pharma Co Ltd Method of producing pyrazino[2,1-c][1,2,4]triazine compound
US9174998B2 (en) * 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
KR102559211B1 (ko) * 2015-06-23 2023-07-25 에자이 알앤드디 매니지먼트 가부시키가이샤 (6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
JP6785487B2 (ja) * 2015-09-18 2020-11-18 国立大学法人鳥取大学 低分子化合物による癌と線維化の抑制と再生促進の効果
WO2017184808A1 (en) * 2016-04-20 2017-10-26 University Of Southern California Compounds and methods for increasing hematopoiesis
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CN110950873A (zh) * 2019-12-10 2020-04-03 河南大学 坡尔吲哚的合成新方法
CA3175150A1 (en) 2020-03-12 2021-09-16 3+2 Pharma LLC Cbp/catenin signaling pathway inhibitors and uses thereof
WO2021183791A1 (en) 2020-03-12 2021-09-16 City Of Hope Wnt/cbp/catenin signaling pathway inhibitors and uses thereof
US20240352020A1 (en) * 2021-08-26 2024-10-24 3+2 Pharma, Llc Pyrazole-containing cbp/catenin antagonists and uses thereof
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3120859A1 (de) 1981-05-26 1982-12-23 Basf Ag, 6700 Ludwigshafen Dihalogenacetamide, verfahren zu ihrer herstellung und herbizide mittel, die acetanilide als herbizide wirkstoffe und diese dihalogenacetamide als antagonistische mittel enthalten
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
EP0656907A1 (en) 1992-08-06 1995-06-14 Molecumetics, Ltd. Conformationally restricted mimetics of reverse turns and peptides containing the same
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5693325A (en) 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US6020331A (en) 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6245764B1 (en) 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6013458A (en) 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
NZ334227A (en) 1996-08-05 2000-10-27 Molecumetics Ltd Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
US6117896A (en) 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6451972B1 (en) 1998-11-16 2002-09-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US6872825B2 (en) 1999-12-21 2005-03-29 The Procter & Gamble Company Peptide β-turn mimetic compounds and processes for making them
DE10005631A1 (de) 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
AU2002333233A1 (en) 2001-07-09 2003-01-29 Pharmacia Italia Spa Interaction inhibitors of tcf-4 with beta-catenin
US6943157B2 (en) * 2001-10-09 2005-09-13 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
JP4387793B2 (ja) * 2001-10-12 2009-12-24 チョンウェ ファーマ コーポレーション 逆向ターンミメティックおよびそれに関連した方法
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
KR20050111588A (ko) 2003-02-13 2005-11-25 사노피-아벤티스 도이칠란트 게엠베하 치환된 헥사하이드로피라지노[1,2-ａ]피리미딘-4,7-디온유도체, 이의 제조방법 및 약제로서의 이의 용도
CA2514791A1 (en) 2003-02-13 2004-08-26 Aventis Pharma Deutschland Gmbh Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments
CN1871239A (zh) * 2003-08-28 2006-11-29 (株)中外制药 β－联蛋白/TCF激活转录的调节
WO2007056593A2 (en) * 2005-11-08 2007-05-18 Choongwae Pharma Corporation α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS
EP1960777B1 (en) 2005-11-28 2009-10-21 Choongwae Pharma Corporation Serum-free expansion of cells in culture
JP5530427B2 (ja) 2008-06-06 2014-06-25 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ アルファへリックスミメティック及び関連の方法

Also Published As

Publication number Publication date
PL2212330T3 (pl) 2015-09-30
MX2010004045A (es) 2010-07-06
ES2622703T3 (es) 2017-07-07
EP2212328B1 (en) 2017-01-25
WO2009051399A3 (en) 2009-06-04
EP2212330A4 (en) 2011-11-30
EP2212330B1 (en) 2015-04-08
EP2212329A2 (en) 2010-08-04
CN101827850B (zh) 2014-03-12
ES2509042T3 (es) 2014-10-16
JP5222949B2 (ja) 2013-06-26
ES2541459T3 (es) 2015-07-20
US8071764B2 (en) 2011-12-06
WO2009051397A2 (en) 2009-04-23
EP2212329A4 (en) 2011-11-30
US20100228027A1 (en) 2010-09-09
JP2011500667A (ja) 2011-01-06
AU2008312193A1 (en) 2009-04-23
WO2009051397A3 (en) 2009-06-04
BRPI0818511B1 (pt) 2021-09-21
BRPI0818647A2 (pt) 2015-04-07
KR101542921B1 (ko) 2015-08-11
US20100222303A1 (en) 2010-09-02
CN101827849A (zh) 2010-09-08
WO2009051397A9 (en) 2010-05-27
KR20100085107A (ko) 2010-07-28
JP5222948B2 (ja) 2013-06-26
US8049008B2 (en) 2011-11-01
CA2702461A1 (en) 2009-04-23
BRPI0818647B1 (pt) 2021-10-26
RU2470024C2 (ru) 2012-12-20
AU2008312191B2 (en) 2012-07-05
KR101269420B1 (ko) 2013-05-30
EP2212330A2 (en) 2010-08-04
EP2212329B1 (en) 2014-07-30
CN103539797A (zh) 2014-01-29
WO2009051399A2 (en) 2009-04-23
RU2010119447A (ru) 2011-11-27
CA2702461C (en) 2012-12-11
US7671054B1 (en) 2010-03-02
JP2011500668A (ja) 2011-01-06
AU2008312193B2 (en) 2012-10-18
CN101896485A (zh) 2010-11-24
RU2457210C2 (ru) 2012-07-27
KR101229504B1 (ko) 2013-02-04
CA2701735C (en) 2012-12-11
US8138337B2 (en) 2012-03-20
CN101827849B (zh) 2013-07-24
CN101827850A (zh) 2010-09-08
WO2009051398A3 (en) 2009-06-04
EP2212328A4 (en) 2011-11-30
WO2009051398A2 (en) 2009-04-23
MX2010004046A (es) 2010-06-25
EP2212328A2 (en) 2010-08-04
CN103539797B (zh) 2016-05-18
KR20100099116A (ko) 2010-09-10
KR20100085102A (ko) 2010-07-28
US20100240662A1 (en) 2010-09-23
CA2701735A1 (en) 2009-04-23
AU2008312191A1 (en) 2009-04-23
JP5400785B2 (ja) 2014-01-29
JP2011500666A (ja) 2011-01-06
RU2010119468A (ru) 2011-11-27

Similar Documents

Publication Publication Date Title
BRPI0818511A2 (pt) Novos compostos de miméticos de giro reverso e uso dos mesmos (1)
BRPI0808013A2 (pt) Compostos de quinoxalina e uso dos mesmos
PT2124638T (pt) Composição de aperfeiçoamento de desempenho e utilização da mesma
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0813355A2 (pt) Compostos de quinazolinona e métodos de uso dos mesmos
BRPI0815811A2 (pt) Derivados de indol substituído e métodos de uso dos mesmos
BRPI0820457A2 (pt) Fluidos de ruptura e métodos de uso dos mesmos
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0720625A2 (pt) Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
BRPI0923725A2 (pt) "compostos absorventes de uv trifuncionais e uso dos mesmos".
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
FI20075532A0 (fi) Uusia esteraaseja ja niiden käyttö
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0810522A2 (pt) Mimétricos diazo bicíclicos de smac e uso dos mesmos.
BRPI0813457A2 (pt) Composto de organoenxofre contendo halogênio e uso do mesmo
DK1954953T3 (da) Gevindforbindelser med coatinger med høj og lav friktion
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BR112012003661A2 (pt) "compostos de biarila e métodos de uso dos mesmos."
BRPI0907365A2 (pt) Composição antimicrobiana e uso
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0914488A2 (pt) "composições de limpeza incluindo siloxanos de sorbitano modificados e uso das mesmas"
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2692 DE 09-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.